Highlights Johnson & Johnson Borsa Italiana

Equities

4JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 14:19:44 2024-06-26 EDT			5-day change	1st Jan Change
137.6 ^EUR	+1.22%		+0.16%	-3.29%

06-24	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE
06-24	J&J: 50M pupils helped through 'Sight for Kids' program	CF

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24	RE
J&J: 50M pupils helped through 'Sight for Kids' program	06-24	CF
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21	MT
Johnson & Johnson: acquisition of Proteologix completed	06-21	CF
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	06-20	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20	CI
J&J: launches open, secure digital ecosystem	06-20	CF
J&J: promising results in Crohn's disease	06-20	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	06-20	DJ
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	06-20	CI
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17	CI
J&J: positive results in Sjögren's disease	06-17	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17	MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15	CI
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm